JPWO2020112905A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020112905A5
JPWO2020112905A5 JP2021529827A JP2021529827A JPWO2020112905A5 JP WO2020112905 A5 JPWO2020112905 A5 JP WO2020112905A5 JP 2021529827 A JP2021529827 A JP 2021529827A JP 2021529827 A JP2021529827 A JP 2021529827A JP WO2020112905 A5 JPWO2020112905 A5 JP WO2020112905A5
Authority
JP
Japan
Prior art keywords
alkyl
pain
heterocycloalkyl
halogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021529827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509206A5 (https=
JP2022509206A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063451 external-priority patent/WO2020112905A1/en
Publication of JP2022509206A publication Critical patent/JP2022509206A/ja
Publication of JP2022509206A5 publication Critical patent/JP2022509206A5/ja
Publication of JPWO2020112905A5 publication Critical patent/JPWO2020112905A5/ja
Pending legal-status Critical Current

Links

JP2021529827A 2018-11-28 2019-11-26 Magl阻害剤による疾病の治療方法 Pending JP2022509206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772554P 2018-11-28 2018-11-28
US62/772,554 2018-11-28
PCT/US2019/063451 WO2020112905A1 (en) 2018-11-28 2019-11-26 Methods of treating disease with magl inhibitors

Publications (3)

Publication Number Publication Date
JP2022509206A JP2022509206A (ja) 2022-01-20
JP2022509206A5 JP2022509206A5 (https=) 2022-11-28
JPWO2020112905A5 true JPWO2020112905A5 (https=) 2022-11-28

Family

ID=70851863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529827A Pending JP2022509206A (ja) 2018-11-28 2019-11-26 Magl阻害剤による疾病の治療方法

Country Status (15)

Country Link
US (1) US20220031676A1 (https=)
EP (1) EP3886844A4 (https=)
JP (1) JP2022509206A (https=)
KR (1) KR20210097734A (https=)
CN (1) CN113347971A (https=)
AU (1) AU2019389017B2 (https=)
BR (1) BR112020015043A2 (https=)
CA (1) CA3120577A1 (https=)
CL (1) CL2021001363A1 (https=)
IL (1) IL283508A (https=)
MA (1) MA54313A (https=)
MX (1) MX2021006312A (https=)
SG (1) SG11202105320YA (https=)
WO (1) WO2020112905A1 (https=)
ZA (1) ZA202103975B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3630744T3 (da) 2017-05-23 2023-03-06 H Lundbeck As Pyrazol-magl-inhibitorer
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
CN117177744A (zh) 2021-01-29 2023-12-05 塞迪拉治疗股份有限公司 Cdk2抑制剂及其使用方法
MX2023015436A (es) 2021-06-26 2024-02-21 Cedilla Therapeutics Inc Inhibidores de cdk2 y metodos de uso de los mismos.
WO2023006893A1 (en) 2021-07-30 2023-02-02 Confo Therapeutics N.V. Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling
CA3234430A1 (en) * 2021-11-02 2023-05-11 Samuel George ANDREW Crystalline forms of a monoacylglycerol lipase inhibitor
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455476B2 (en) * 2009-04-22 2013-06-04 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10570146B2 (en) * 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
WO2017087858A1 (en) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
CN108601769B (zh) * 2015-11-20 2021-09-03 H.隆德贝克有限公司 吡唑化合物及其制备和使用方法
KR20170128029A (ko) * 2016-05-13 2017-11-22 삼성에스디아이 주식회사 태양전지 전극 형성용 조성물 및 이로부터 제조된 전극
CN110198944A (zh) * 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
DK3630744T3 (da) * 2017-05-23 2023-03-06 H Lundbeck As Pyrazol-magl-inhibitorer
US10927105B1 (en) * 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors

Similar Documents

Publication Publication Date Title
AU2020350745B2 (en) Fused pyridone compound, and preparation method therefor and use thereof
CN109863140B (zh) 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺
KR101450172B1 (ko) 페놀 유도체 및 이의 약학적 또는 화장품 용도
AU2018255300A1 (en) Bicyclic compounds and their use in the treatment of cancer
US20200299269A1 (en) Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
TW201204346A (en) Novel hydroxamic acid derivative
TW200911232A (en) Novel therapeutic compounds
RU2011147200A (ru) Азетидинилдиамиды в качестве ингибиторов моноациглицерин-липазы
AU2012248223A1 (en) Amide compound and pharmaceutical application therefor
JP2014506599A5 (https=)
BR112015019634B1 (pt) Derivados de pirrolo[2,3-d]pirimidina como inibidores de janus kinase (jak), seu uso e composição farmacêutica ou veterinária que os compreende
JP2009534406A5 (https=)
JP2017525677A5 (https=)
AU2015337607A1 (en) Substituted dihydropyrrolopyrazole compound
EA037643B1 (ru) Замещенные фенилоксазолидиноны для антимикробной терапии
JP2023528073A (ja) Gpr65モジュレーターとしてのn-フェニルアミノカルボニル、ピリジノ-、ピリミジノ及びベンゾトロパン
JPWO2020112905A5 (https=)
JPWO2018217809A5 (https=)
JP7734874B2 (ja) 新規なacc阻害剤
AU2020338985A1 (en) Substituted urea dihydroorotate dehydrogenase inhibitors
JPWO2020033520A5 (https=)
RU2019109570A (ru) 8-(азетидин-1-ил)-[1,2,4]триазоло[1,5-а]пиридинилы, композиции и способы их применения
JPWO2019213470A5 (https=)
TW202513565A (zh) Prmt5抑制劑及其用途
AU2019351530A1 (en) MDM2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof